StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Jazz Pharmaceuticals (JAZZ) PT Lowered to $187 at BMO Capital
March 2, 2022 7:47 AM
BMO Capital analyst Gary Nachman lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $187.00 (from $202.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS View
Analyst PT Change
Next Articles
Jazz Pharmaceuticals (JAZZ) PT Lowered to $214 at RBC Capital
March 2, 2022 6:37 AM
Jazz Pharmaceuticals (JAZZ) Guidance Looks Conservative After Printing a 43% Conversion Rate - Morgan Stanley
March 2, 2022 6:33 AM
Needham & Company Reiterates Jazz Pharmaceuticals (JAZZ) at Buy on Earnings, Analyst Doesn't Expect Stock to Uptick Short-Term, but Highlights Strong Execution and Fundamentals
March 2, 2022 6:23 AM
Jazz Pharmaceuticals (JAZZ) PT Raised to $202 at Goldman Sachs
March 2, 2022 6:21 AM
Form S-8 Jazz Pharmaceuticals
March 2, 2022 6:14 AM
Jazz Pharmaceuticals (JAZZ) PT Lowered to $197 at Piper Sandler
March 2, 2022 6:14 AM
Form 10-K Jazz Pharmaceuticals For: Dec 31
March 1, 2022 6:00 PM
Form 8-K Jazz Pharmaceuticals For: Mar 01
March 1, 2022 4:14 PM
Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 58c
March 1, 2022 4:14 PM
